Post by Tony Crispino on May 6, 2017 13:43:11 GMT -8
The American Urological Association (AUA) will be releasing their new Localized Cancer of the Prostate (LCaP) treatment guidelines next Friday May 12 during the AUA2017 Conference Plenary Session. I am very familiar with every guideline statement in detail as I co-authored the guidelines. I am proud to have been a part of this work which took nearly two years to complete. The AUA guidelines differ from the National Comprehensive Cancer Network (NCCN) in various ways but they largely do not conflict with them as we did use the NCCN guidelines as reference material along with many other trials and studies. Arriving at 68 "consensus" statements meant compromise and understanding from a panel comprised of urologists, radiation oncologists, medical oncologists, and a patient advocate.
My colleagues, whose names will be announced on the 12th, were excellent to work with. They treated me very fairly and with respect. They accepted me very seriously and allowed me to comment on the science, wording, and weighing the evidence of each statement.
I cannot comment as yet on the statements and I will be under non-disclosure for 12 months after the release date of the guidelines. Meaning, I cannot state who said what and why the statement was made. But I can acknowledge being on the panel as will be disclosed Friday. I had no disclosures to declare though I did disclose my involvement in institutions that did receive funds from many private resources.
Again I think the panelists were very fair and expressed surprise of my knowledge of each detail I provided input on. I thank them and the AUA for having me serve on this panel. It was an honor to be the very first patient advocate to serve on this panel.
My colleagues, whose names will be announced on the 12th, were excellent to work with. They treated me very fairly and with respect. They accepted me very seriously and allowed me to comment on the science, wording, and weighing the evidence of each statement.
I cannot comment as yet on the statements and I will be under non-disclosure for 12 months after the release date of the guidelines. Meaning, I cannot state who said what and why the statement was made. But I can acknowledge being on the panel as will be disclosed Friday. I had no disclosures to declare though I did disclose my involvement in institutions that did receive funds from many private resources.
Again I think the panelists were very fair and expressed surprise of my knowledge of each detail I provided input on. I thank them and the AUA for having me serve on this panel. It was an honor to be the very first patient advocate to serve on this panel.